“…The measurement of the PIPR allows for the direct and in vivo assessment of ipRGC function in humans (Adhikari et al, 2015b;Feigl & Zele, 2014;Gamlin et al, 2007;Kankipati et al, 2010;Markwell et al, 2010;McDougal et al, 2010;Young et al, 2008). Collectively, the PIPR has been assessed as a direct and non-invasive biomarker of ipRGC function in human eyes with and without retinal disease (Adhikari, Zele, Thomas, & Feigl, 2016b;Feigl, Mattes, Thomas, & Zele, 2011;Feigl et al, 2014;Feigl, Zele, Fader, Howes, Hughes, Jones, & Jones, 2012;Kankipati et al, 2010;Kankipati, Girkin, & Gamlin, 2011;Kelbsch, Maeda, Strasser, Blumenstock, Wilhelm, Wilhelm, & Peters, 2016;Markwell et al, 2010;Maynard, Zele, & Feigl, 2015) and therefore can also be used to measure the input of ipRGC projections to the brain mood centres to evaluate the melanopsin function in depressive disorders (Laurenzo et al, 2016;Roecklein et al, 2013).…”